The agency is looking to lift the longstanding NCD that restricts patients to one amyloid-detecting positron emission tomography exam in their lifetime.

Payment cuts in Medicare, rising costs and administrative burdens all are pushing providers to seek sales, the AMA said Wednesday.

Imaging advocates blasted the proposal shortly after its release, saying it’s “unconscionable that radiology is again on the chopping block.”

The nation’s largest imaging group has hired Barclays, hoping to raise “preferred equity” with a portion of its debts coming due in the next 2 years.

The Paris, France-based artificial intelligence developer will use the money to expand its product portfolio and headcount.

The Germany-based corporation said this is the “only contrast agent approved for this indication” in America.

Other imaging-related startup companies recently raising $4.9M or more include Altis Labs, BrainTale, Leadoptik and Hypervision Surgical.

The boost comes after the Los Angeles-based imaging center chain recently closed a $259M public stock offering, with a sizable chunk earmarked for expansion initiatives.